Circulating Angiogenic Factors and the Risk of Preeclampsia
Top Cited Papers
- 12 February 2004
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (7) , 672-683
- https://doi.org/10.1056/nejmoa031884
Abstract
The cause of preeclampsia remains unclear. Limited data suggest that excess circulating soluble fms-like tyrosine kinase 1 (sFlt-1), which binds placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), may have a pathogenic role. We performed a nested case–control study within the Calcium for Preeclampsia Prevention trial, which involved healthy nulliparous women. Each woman with preeclampsia was matched to one normotensive control. A total of 120 pairs of women were randomly chosen. Serum concentrations of angiogenic factors (total sFlt-1, free PlGF, and free VEGF) were measured throughout pregnancy; there were a total of 655 serum specimens. The data were analyzed cross-sectionally within intervals of gestational age and according to the time before the onset of preeclampsia. During the last two months of pregnancy in the normotensive controls, the level of sFlt-1 increased and the level of PlGF decreased. These changes occurred earlier and were more pronounced in the women in whom preeclampsia later developed. The sFlt-1 level increased beginning approximately five weeks before the onset of preeclampsia. At the onset of clinical disease, the mean serum level in the women with preeclampsia was 4382 pg per milliliter, as compared with 1643 pg per milliliter in controls with fetuses of similar gestational age (P<0.001). The PlGF levels were significantly lower in the women who later had preeclampsia than in the controls beginning at 13 to 16 weeks of gestation (mean, 90 pg per milliliter vs. 142 pg per milliliter, P=0.01), with the greatest difference occurring during the weeks before the onset of preeclampsia, coincident with the increase in the sFlt-1 level. Alterations in the levels of sFlt-1 and free PlGF were greater in women with an earlier onset of preeclampsia and in women in whom preeclampsia was associated with a small-for-gestational-age infant. Increased levels of sFlt-1 and reduced levels of PlGF predict the subsequent development of preeclampsia.Keywords
This publication has 24 references indexed in Scilit:
- Overexpression of the Soluble Vascular Endothelial Growth Factor Receptor in Preeclamptic Patients: Pathophysiological ConsequencesJournal of Clinical Endocrinology & Metabolism, 2003
- Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsiaObstetrics & Gynecology, 2003
- Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR-1) Levels in Women with PreeclampsiaJournal of Clinical Endocrinology & Metabolism, 2003
- Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsiaJournal of Clinical Investigation, 2003
- Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets SyndromeThe American Journal of Pathology, 2002
- Pathogenesis and genetics of pre-eclampsiaThe Lancet, 2001
- Pre-eclampsiaThe Lancet, 2000
- Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsiaNature, 2000
- Disturbed Feto-Maternal Cell Traffic in PreeclampsiaPublished by Wolters Kluwer Health ,2000
- Human placental syncytiotrophoblast microvillous membranes impair maternal vascular endothelial functionBJOG: An International Journal of Obstetrics and Gynaecology, 1997